{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:48:23Z","timestamp":1785509303109,"version":"3.56.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Peking Union Medical College Hospital Talent Cultivation Program Category D","award":["UHB11983"],"award-info":[{"award-number":["UHB11983"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82573978"],"award-info":[{"award-number":["82573978"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Beijing Key Clinical Specialty Construction Project"},{"name":"National Key Clinical Specialty Project of China"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"DOI":"10.1186\/s12944-026-02974-7","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T02:35:39Z","timestamp":1778294139000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Phenotype-dependent effects of IL-17A inhibitors on lipid profiles in moderate-to-severe plaque psoriasis: a retrospective cohort study"],"prefix":"10.1186","volume":"25","author":[{"given":"Chao","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Fan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dian-Mo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Xia","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Zhong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"issue":"2","key":"2974_CR1","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/jid.2012.339","volume":"133","author":"R Parisi","year":"2013","unstructured":"Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377\u201385. https:\/\/doi.org\/10.1038\/jid.2012.339.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"2974_CR2","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/jdv.15159","volume":"33","author":"JM Fernandez-Armenteros","year":"2019","unstructured":"Fernandez-Armenteros JM, Gomez-Arbones X, Buti-Soler M, Betriu-Bars A, Sanmartin-Novell V, Ortega-Bravo M, et al. Psoriasis, metabolic syndrome and cardiovascular risk factors. A population-based study. J Eur Acad Dermatol Venereol. 2019;33(1):128\u201335. https:\/\/doi.org\/10.1111\/jdv.15159.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"2974_CR3","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1186\/s12916-022-02617-5","volume":"20","author":"L Zhang","year":"2022","unstructured":"Zhang L, Wang Y, Qiu L, Wu J. Psoriasis and cardiovascular disease risk in European and East Asian populations: evidence from meta-analysis and Mendelian randomization analysis. BMC Med. 2022;20(1):421. https:\/\/doi.org\/10.1186\/s12916-022-02617-5.","journal-title":"BMC Med"},{"issue":"13","key":"2974_CR4","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.jacc.2021.02.009","volume":"77","author":"MS Garshick","year":"2021","unstructured":"Garshick MS, Ward NL, Krueger JG, Berger JS. Cardiovascular Risk in Patients With Psoriasis: JACC Review Topic of the Week. J Am Coll Cardiol. 2021;77(13):1670\u201380. https:\/\/doi.org\/10.1016\/j.jacc.2021.02.009.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"2974_CR5","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1111\/jdv.16273","volume":"34","author":"A Egeberg","year":"2020","unstructured":"Egeberg A, Gisondi P, Carrascosa JM, Warren RB, Mrowietz U. The role of the interleukin-23\/Th17 pathway in cardiometabolic comorbidity associated with psoriasis. J Eur Acad Dermatol Venereol. 2020;34(8):1695\u2013706. https:\/\/doi.org\/10.1111\/jdv.16273.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"2974_CR6","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamadermatol.2022.0364","volume":"158","author":"L Pina Vegas","year":"2022","unstructured":"Pina Vegas L, Penso L, Claudepierre P, Sbidian E. Long-term persistence of first-line biologics for patients with psoriasis and psoriatic arthritis in the French health insurance database. JAMA Dermatol. 2022;158(5):513\u201322. https:\/\/doi.org\/10.1001\/jamadermatol.2022.0364.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"2974_CR7","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/bjd.18245","volume":"182","author":"NJ Korman","year":"2020","unstructured":"Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020;182(4):840\u20138. https:\/\/doi.org\/10.1111\/bjd.18245.","journal-title":"Br J Dermatol"},{"key":"2974_CR8","doi-asserted-by":"publisher","unstructured":"Merola JF, McInnes IB, Deodhar AA, Dey AK, Adamstein NH, Quebe-Fehling E, et al. Effect of secukinumab on traditional cardiovascular risk factors and inflammatory biomarkers: post hoc analyses of pooled data across three indications. Rheumatol Ther. 2022;9(3):935\u201355. \u00a0 https:\/\/doi.org\/10.1007\/s40744-022-00434-z.","DOI":"10.1007\/s40744-022-00434-z"},{"key":"2974_CR9","doi-asserted-by":"publisher","first-page":"204062232094477","DOI":"10.1177\/2040622320944777","volume":"11","author":"HN Wang","year":"2020","unstructured":"Wang HN, Huang YH. Changes in metabolic parameters in psoriatic patients treated with secukinumab. Ther Adv Chronic Dis. 2020;11:2040622320944777. https:\/\/doi.org\/10.1177\/2040622320944777.","journal-title":"Ther Adv Chronic Dis"},{"issue":"1","key":"2974_CR10","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s13555-024-01327-5","volume":"15","author":"A Smith","year":"2025","unstructured":"Smith A, Karahasan A, Yi D, Yapabandara S, Elhindi J, Fernandez-Penas P, et al. Biologic therapy and cardiometabolic risk in psoriasis: a retrospective review. Dermatol Ther (Heidelb). 2025;15(1):201\u201312. https:\/\/doi.org\/10.1007\/s13555-024-01327-5.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"2974_CR11","doi-asserted-by":"publisher","first-page":"934","DOI":"10.19723\/j.issn.1671-167X.2025.05.018","volume":"57","author":"X Liu","year":"2025","unstructured":"Liu X, Lin Y, Guo J. [Influence of long-term biologic therapy on metabolic biochemical parameters in moderate to severe plaque psoriasis]. Beijing Da Xue Xue Bao Yi Xue Ban. 2025;57(5):934\u201340. https:\/\/doi.org\/10.19723\/j.issn.1671-167X.2025.05.018.","journal-title":"Beijing Da Xue Xue Bao Yi Xue Ban"},{"issue":"1","key":"2974_CR12","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaad.2018.02.074","volume":"79","author":"A Egeberg","year":"2018","unstructured":"Egeberg A, Wu JJ, Korman N, Solomon JA, Goldblum O, Zhao F, et al. Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3. J Am Acad Dermatol. 2018;79(1):104\u2013e1098. https:\/\/doi.org\/10.1016\/j.jaad.2018.02.074.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"2974_CR13","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.jid.2020.01.025","volume":"140","author":"JM Gelfand","year":"2020","unstructured":"Gelfand JM, Shin DB, Duffin KC, Armstrong AW, Blauvelt A, Tyring SK, et al. A randomized placebo-controlled trial of secukinumab on aortic vascular inflammation in moderate-to-severe plaque psoriasis (VIP-S). J Invest Dermatol. 2020;140(9):1784\u2013e17932. https:\/\/doi.org\/10.1016\/j.jid.2020.01.025.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"2974_CR14","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.3390\/jcm12051934","volume":"12","author":"T Hagino","year":"2023","unstructured":"Hagino T, Saeki H, Fujimoto E, Kanda N. Effects of biologic therapy on laboratory indicators of cardiometabolic diseases in patients with psoriasis. J Clin Med. 2023;12(5):1934. https:\/\/doi.org\/10.3390\/jcm12051934.","journal-title":"J Clin Med"},{"issue":"7","key":"2974_CR15","doi-asserted-by":"publisher","first-page":"573","DOI":"10.35541\/cjd.20220839","volume":"56","author":"Committee on Psoriasis, Chinese Society of Dermatology","year":"2023","unstructured":"Committee on Psoriasis, Chinese Society of Dermatology. Guideline for the diagnosis and treatment of psoriasis in China (2023 edition). Chin J Dermatol. 2023;56(7):573\u20137. https:\/\/doi.org\/10.35541\/cjd.20220839.","journal-title":"Chin J Dermatol"},{"key":"2974_CR16","doi-asserted-by":"publisher","first-page":"1190934","DOI":"10.3389\/fphar.2023.1190934","volume":"14","author":"JJ Li","year":"2023","unstructured":"Li JJ, Zhao SP, Zhao D, Lu GP, Peng DQ, Liu J, et al. 2023 Chinese guideline for lipid management. Front Pharmacol. 2023;14:1190934. https:\/\/doi.org\/10.3389\/fphar.2023.1190934.","journal-title":"Front Pharmacol"},{"issue":"5","key":"2974_CR17","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3760\/cma.j.cn112338-20220402-00253","volume":"43","author":"Chinese Nutrition Society Obesity Prevention and Control Section, Chinese Nutrition Society Clinical Nutrition Section, Chinese Preventive Medicine Association Behavioral Health Section, Chinese Preventive Medicine Association Sports and Health Section","year":"2022","unstructured":"Chinese Nutrition Society Obesity Prevention and Control Section, Chinese Nutrition Society Clinical Nutrition Section, Chinese Preventive Medicine Association Behavioral Health Section, Chinese Preventive Medicine Association Sports and Health Section. Expert consensus on obesity prevention and treatment in China. Chin J Epidemiol. 2022;43(5):609\u201326. https:\/\/doi.org\/10.3760\/cma.j.cn112338-20220402-00253.","journal-title":"Chin J Epidemiol"},{"issue":"6","key":"2974_CR18","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/jdv.18044","volume":"36","author":"JJ Wu","year":"2022","unstructured":"Wu JJ, Kavanaugh A, Lebwohl MG, Gniadecki R, Merola JF. Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2022;36(6):797\u2013806. https:\/\/doi.org\/10.1111\/jdv.18044.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"2974_CR19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s13679-023-00518-z","volume":"12","author":"J Vekic","year":"2023","unstructured":"Vekic J, Stefanovic A, Zeljkovic A. Obesity and dyslipidemia: a review of current evidence. Curr Obes Rep. 2023;12(3):207\u201322. https:\/\/doi.org\/10.1007\/s13679-023-00518-z.","journal-title":"Curr Obes Rep"},{"issue":"6","key":"2974_CR20","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3390\/life14060733","volume":"14","author":"E Scala","year":"2024","unstructured":"Scala E, Mercurio L, Albanesi C, Madonna S. The intersection of the pathogenic processes underlying psoriasis and the comorbid condition of obesity. Life. 2024;14(6):733. https:\/\/doi.org\/10.3390\/life14060733.","journal-title":"Life"},{"key":"2974_CR21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.molmet.2018.05.008","volume":"15","author":"BT Palmisano","year":"2018","unstructured":"Palmisano BT, Zhu L, Eckel RH, Stafford JM. Sex differences in lipid and lipoprotein metabolism. Mol Metab. 2018;15:45\u201355. https:\/\/doi.org\/10.1016\/j.molmet.2018.05.008.","journal-title":"Mol Metab"},{"issue":"6","key":"2974_CR22","doi-asserted-by":"publisher","first-page":"e14281","DOI":"10.1111\/dth.14281","volume":"33","author":"P Gisondi","year":"2020","unstructured":"Gisondi P, Bellinato F, Bruni M, De Angelis G, Girolomoni G. Methotrexate vs secukinumab safety in psoriasis patients with metabolic syndrome. Dermatol Ther. 2020;33(6):e14281. https:\/\/doi.org\/10.1111\/dth.14281.","journal-title":"Dermatol Ther"},{"issue":"3","key":"2974_CR23","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/jdv.16004","volume":"34","author":"S Gerdes","year":"2020","unstructured":"Gerdes S, Pinter A, Papavassilis C, Reinhardt M. Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients. J Eur Acad Dermatol Venereol. 2020;34(3):533\u201341. https:\/\/doi.org\/10.1111\/jdv.16004.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"2974_CR24","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3390\/life11060535","volume":"11","author":"EA Piros","year":"2021","unstructured":"Piros EA, Szabo A, Rencz F, Brodszky V, Wikonkal N, Miheller P, et al. Anti-interleukin-17 therapy of severe psoriatic patients results in an improvement of serum lipid and inflammatory parameters\u2019 levels, but has no effect on body composition parameters. Life (Basel). 2021;11(6):535. https:\/\/doi.org\/10.3390\/life11060535.","journal-title":"Life (Basel)"},{"issue":"5","key":"2974_CR25","doi-asserted-by":"publisher","first-page":"e683","DOI":"10.1111\/jdv.18830","volume":"37","author":"K Kridin","year":"2023","unstructured":"Kridin K, Mruwat N, Thaci D, Ludwig RJ. The cardiometabolic safety of interleukin 23 versus interleukin 17 inhibitors in psoriasis: a large-scale global cohort study. J Eur Acad Dermatol Venereol. 2023;37(5):e683\u20135. https:\/\/doi.org\/10.1111\/jdv.18830.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"2974_CR26","doi-asserted-by":"publisher","first-page":"2425029","DOI":"10.1080\/09546634.2024.2425029","volume":"35","author":"L Ibba","year":"2024","unstructured":"Ibba L, Di Giulio S, Gargiulo L, Facheris P, Perugini C, Costanzo A, et al. Long-term effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis with and without cardiometabolic comorbidities: a single-center retrospective study. J Dermatolog Treat. 2024;35(1):2425029. https:\/\/doi.org\/10.1080\/09546634.2024.2425029.","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"2974_CR27","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/j.bbadis.2017.01.027","volume":"1863","author":"T Shen","year":"2017","unstructured":"Shen T, Chen X, Li Y, Tang X, Jiang X, Yu C, et al. Interleukin-17A exacerbates high-fat diet-induced hepatic steatosis by inhibiting fatty acid \u03b2-oxidation. Biochim Biophys Acta Mol Basis Dis. 2017;1863(6):1510\u20138. https:\/\/doi.org\/10.1016\/j.bbadis.2017.01.027.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"2974_CR28","doi-asserted-by":"publisher","first-page":"253046","DOI":"10.1155\/2013\/253046","volume":"2013","author":"W Shi","year":"2013","unstructured":"Shi W, Zhu Q, Gu J, Liu X, Lu L, Qian X, et al. Anti-IL-17 antibody improves hepatic steatosis by suppressing interleukin-17-related fatty acid synthesis and metabolism. Clin Dev Immunol. 2013;2013:253046. https:\/\/doi.org\/10.1155\/2013\/253046.","journal-title":"Clin Dev Immunol"},{"issue":"11","key":"2974_CR29","doi-asserted-by":"publisher","first-page":"6947","DOI":"10.4049\/jimmunol.1001269","volume":"185","author":"LA Zuniga","year":"2010","unstructured":"Zuniga LA, Shen WJ, Joyce-Shaikh B, Pyatova EA, Richards AG, Thom C, et al. IL-17 regulates adipogenesis, glucose homeostasis, and obesity. J Immunol. 2010;185(11):6947\u201359. https:\/\/doi.org\/10.4049\/jimmunol.1001269.","journal-title":"J Immunol"},{"issue":"9","key":"2974_CR30","doi-asserted-by":"publisher","first-page":"5619","DOI":"10.4049\/jimmunol.1001879","volume":"185","author":"S Chen","year":"2010","unstructured":"Chen S, Shimada K, Zhang W, Huang G, Crother TR, Arditi M. IL-17A is proatherogenic in high-fat diet-induced and Chlamydia pneumoniae infection-accelerated atherosclerosis in mice. J Immunol. 2010;185(9):5619\u201327. https:\/\/doi.org\/10.4049\/jimmunol.1001879.","journal-title":"J Immunol"},{"issue":"8","key":"2974_CR31","doi-asserted-by":"publisher","first-page":"e73861","DOI":"10.1371\/journal.pone.0073861","volume":"8","author":"TR Cimato","year":"2013","unstructured":"Cimato TR, Palka BA, Lang JK, Young RF. LDL cholesterol modulates human CD34\u2009+\u2009HSPCs through effects on proliferation and the IL-17 G-CSF axis. PLoS ONE. 2013;8(8):e73861. https:\/\/doi.org\/10.1371\/journal.pone.0073861.","journal-title":"PLoS ONE"},{"key":"2974_CR32","doi-asserted-by":"publisher","first-page":"107879","DOI":"10.1016\/j.phrs.2025.107879","volume":"219","author":"L Ma","year":"2025","unstructured":"Ma L, Yang W, Gao W, Liu X, Dong M, An G, et al. IL-17 as a therapeutic target in cardiovascular diseases: mechanistic insights and translational opportunities. Pharmacol Res. 2025;219:107879. https:\/\/doi.org\/10.1016\/j.phrs.2025.107879.","journal-title":"Pharmacol Res"},{"issue":"2","key":"2974_CR33","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.eprac.2024.09.016","volume":"31","author":"SB Patel","year":"2025","unstructured":"Patel SB, Wyne KL, Afreen S, Belalcazar LM, Bird MD, Coles S, et al. American association of clinical endocrinology clinical practice guideline on pharmacologic management of adults with dyslipidemia. Endocr Pract. 2025;31(2):236\u201362. https:\/\/doi.org\/10.1016\/j.eprac.2024.09.016.","journal-title":"Endocr Pract"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-026-02974-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-026-02974-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-026-02974-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:58:52Z","timestamp":1783011532000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12944-026-02974-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2974"],"URL":"https:\/\/doi.org\/10.1186\/s12944-026-02974-7","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the institutional review board of Peking Union Medical College Hospital (Approval number: I-25PJ2973). The requirement for informed patient consent was waived because of the anonymous nature of the data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"163"}}